---
title: "Medicenna Therapeutics Corp. (MDNAF.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/MDNAF.US.md"
symbol: "MDNAF.US"
name: "Medicenna Therapeutics Corp."
industry: "生物技术"
---

# Medicenna Therapeutics Corp. (MDNAF.US)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |
| Location | 美股市场 |
| Website | [www.medicenna.com](https://www.medicenna.com) |

## Company Profile

Medicenna Therapeutics Corp.（医明纳治疗公司）是一家免疫疗法公司，致力于开发和商业化用于治疗癌症和其他疾病的超级细胞因子和强化型超级细胞因子。该公司开发了 bizaxofusp（MDNA55），一种用于治疗复发性胶质母细胞瘤和脑肿瘤的白细胞介素-4（IL-4）EC。该公司还开发了 MDNA11，这是 IL-2 的增强版本，可激活和增殖抗击癌症所需的免疫细胞；MDNA209，一种 IL-2 拮抗剂，用于治疗自身免疫性疾病，如多发性硬化和移植物抗宿主病；MDNA413，一种双重 IL-4/IL-13 拮抗剂，用于治疗癌症免疫疗法；MDNA113，一种假面双功能抗 PD1...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -6.27 | 398/603 | - | - | - |
| PB | 12.93 | 383/603 | 7.94 | 5.50 | 4.53 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-17T05:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 4 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.68 |
| Highest Target | 4.00 |
| Lowest Target | 2.50 |

## References

- [Company Overview](https://longbridge.com/en/quote/MDNAF.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/MDNAF.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/MDNAF.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.